-
1.发明公开
公开(公告)号：EP4061794A1
公开(公告)日：2022-09-28
申请号：EP20824741.1
申请日：2020-11-17
申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services , The University of Maryland, Baltimore
发明人： MORRIS, Patrick Joseph , THOMAS, Craig Joseph , BYARD, Stephen J. , WILMSHURST, Martin P. , GOULD, Todd , MOADDEL, Ruin , ZARATE, Carlos
IPC分类号： C07C53/126 , C07C55/08 , C07C59/06 , C07C65/10 , C07C225/20 , A61P25/18 , A61P25/22 , A61P25/24 , A61K31/135
-
公开(公告)号：EP3432869A1
公开(公告)日：2019-01-30
申请号：EP17716697.2
申请日：2017-03-27
申请人： THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services , University of Maryland, Baltimore
发明人： WAINER, Irving , ZARATE, Carlos , MOADDEL, Ruin , GOULD, Todd , ZANOS, Panos , THOMAS, Craig , MORRIS, Patrick
IPC分类号： A61K31/135 , A61P25/28 , A61P25/24
-
公开(公告)号：EP3904332A1
公开(公告)日：2021-11-03
申请号：EP21177619.0
申请日：2012-10-15
申请人： The United States of America, as represented by The Secretary, Department of Health and Human Services , The Cooper Health System , SRI International
发明人： WAINER, Irving, W. , MOADDEL, Ruin , BERNIER, Michel , ZARATE, Carlos, A. , TORJMAN, Marc, C. , GOLDBERG, Michael, E. , TANGA, Mary, J.
IPC分类号： C07C225/20 , A61K31/135 , A61P21/02 , A61P25/00 , A61P25/04 , A61P25/18 , A61P25/24 , A61P25/28 , A61P29/00
摘要： The disclosure provides a pharmaceutical composition comprising a compound of the Formula
or
or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient, wherein the composition is formulated for oral administration to a human and contains 0.2 mg to 500 mg of the compound or a salt thereof.-
4.发明公开THE USE OF (2R, 6R)-HYDROXYNORKETAMINE, (S)-DEHYDRONORKETAMINE AND OTHER STEREOISOMERIC DEHYDRO AND HYDROXYLATED METABOLITES OF (R,S)- KETAMINE IN THE TREATMENT OF DEPRESSION AND NEUROPATHIC PAIN 审中-公开氯胺酮在抑郁症和神经性疼痛的治疗 - 的（R，S）的（2R，6R）-HYDROXYNORKETAMIN，（S）AND OTHER -DEHYDRONORKETAMIN立体异构脱氢USE和羟基化的代谢产物
公开(公告)号：EP2766339A1
公开(公告)日：2014-08-20
申请号：EP12783752.4
申请日：2012-10-15
申请人： The United States Of America, As Represented By The Secretary, Department Of Health And Human Services , The Cooper Health System
发明人： WAINER, Irving, W. , MOADDEL, Ruin , BERNIER, Michel , ZARATE, Carlos, A. , TORJMAN, Marc, C. , GOLDBERG, Michael, E. , TANGA, Mary, J.
IPC分类号： C07C225/20 , C07C237/02 , C07D295/155 , C07D295/145 , A61P25/04 , A61P25/28 , A61P25/00 , A61K31/133 , A61K31/122
CPC分类号： A61K31/5375 , A61K31/137 , A61K31/165 , A61K31/222 , A61K31/24 , A61K31/265 , A61K31/4453 , C07B2200/07 , C07C225/20 , C07C229/48 , C07C237/04 , C07C237/20 , C07C2601/14 , C07C2601/16 , C07D295/108 , C07D295/112 , C07D295/15 , C07D295/155
摘要： The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain disorder (CRPS) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
摘要翻译： 因此，本发明提供了新颖的氯胺酮代谢物的前体药物。 本公开提供治疗双相抑郁症，重度抑郁症，神经性疼痛和慢性疼痛，包括复杂区域疼痛合成疼痛障碍（CRPD）通过给予纯化氯胺酮的代谢产物或代谢氯胺酮前体药物直接有需要的患者寻求治疗的方法。
-
5.发明公开
公开(公告)号：EP3433230A1
公开(公告)日：2019-01-30
申请号：EP17716350.8
申请日：2017-03-27
申请人： The U.S.A. as represented by the Secretary, Department of Health and Human Services , University of Maryland, Baltimore
发明人： THOMAS, Craig , MORRIS, Patrick , ZARATE, Carlos , MOADDEL, Ruin , GOULD, Todd , ZANOS, Panos
IPC分类号： C07C225/22 , A61K31/133
-
-
-
-
搜索结果
5 条记录 (耗时 0.03 秒)
